Brisbane, Australia, 2 August 2018 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the completion of paediatric enrolment in the prospective, double-blind stage of its Breathe Easy study. A total of 681 paediatric patients have been recruited at Joondalup Health Campus and Princess Margaret Hospital in Perth, Australia. The Breathe Easy study is evaluating the efficacy of ResApp’s smartphone application for the diagnosis of childhood acute respiratory disease using cough sounds and will be used to support European (CE) and Australian (TGA) regulatory submissions.
“We are very grateful to all the patients who participated in the study as well as their parents. We also appreciate the sterling efforts of the clinical teams at Joondalup and Princess Margaret who have done an outstanding job in recording high quality audio and preparing consistent clinical data,” said Tony Keating, CEO and Managing Director of ResApp. “Results from the Breathe Easy study are expected this month, before SMARTCOUGH-C-2 results have been finalised. Upon receipt, we will move quickly forward with regulatory submissions for Europe and Australia.”
With enrolment now complete, the study enters the data verification phase, where final quality assurance as well as clinical adjudication will be conducted for the remaining patients. Following data verification, an independent team of health researchers from Curtin University will prepare top-line results, which are expected this month.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies underway at leading hospitals in the United States and Australia have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a proof-of-concept clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.